Who is sponsoring NCT05937919?

NCT05937919 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05937919?

Interventions in NCT05937919: Intravenous injection of 68Ga-PMD22.

What condition does NCT05937919 study?

NCT05937919 studies Gastrointestinal Cancer.

Is NCT05937919 still recruiting?

NCT05937919 is currently status unknown. Last updated 10 July 2023.

Last reviewed 2023-07-10 · How we verify

NCT05937919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-PMD22 PET/CT Examination Targeting CLDN18.2

Status unknown EARLY_PHASE1 Last updated 10 July 2023

What this trial tests

EARLY_PHASE1 trial testing Intravenous injection of 68Ga-PMD22 in Gastrointestinal Cancer in 10 participants. Status unknown.

Timeline

28 May 2023

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	10
Start date	28 May 2023
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across China

Drugs / interventions tested

Intravenous injection of 68Ga-PMD22 — full drug profile →

Conditions studied

Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

Under 80, any sex, with Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the ability of the CLDN18.2-targeted 68Ga-PMD22 tracer to detect CLDN18.2 expression in patients with gastric and colorectal cancer and other gastrointestinal tumours.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.
Maksymova L, Pilger YA, Nuhn L, Van Ginderachter JA. · · 2025 · cited 24× · PMID 40033293 · DOI 10.1186/s12943-025-02270-5
Antibody-mediated targeting of Claudins in cancer.
Vonniessen B, Tabariès S, Siegel PM. · · 2024 · cited 12× · PMID 38371623 · DOI 10.3389/fonc.2024.1320766
Synthesis, preclinical evaluation and pilot clinical translation of [<sup>68</sup>Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer.
Wang R, Bai Z, Zhong W, Li C, et al · · 2024 · cited 8× · PMID 38926162 · DOI 10.1007/s00259-024-06808-5

Verify or expand the search:

Other recruiting trials for Gastrointestinal Cancer

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05937919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 10 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05937919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing